GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Caplin Point Laboratories Ltd (BOM:524742) » Definitions » Gross Profit

Caplin Point Laboratories (BOM:524742) Gross Profit : ₹9,699 Mil (TTM As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Caplin Point Laboratories Gross Profit?

Caplin Point Laboratories's gross profit for the three months ended in Mar. 2024 was ₹2,619 Mil. Caplin Point Laboratories's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was ₹9,699 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Caplin Point Laboratories's gross profit for the three months ended in Mar. 2024 was ₹2,619 Mil. Caplin Point Laboratories's Revenue for the three months ended in Mar. 2024 was ₹4,532 Mil. Therefore, Caplin Point Laboratories's Gross Margin % for the quarter that ended in Mar. 2024 was 57.78%.

Caplin Point Laboratories had a gross margin of 57.78% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Caplin Point Laboratories was 57.25%. The lowest was 43.19%. And the median was 54.73%.


Caplin Point Laboratories Gross Profit Historical Data

The historical data trend for Caplin Point Laboratories's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caplin Point Laboratories Gross Profit Chart

Caplin Point Laboratories Annual Data
Trend Jun15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,280.30 5,731.60 7,119.00 8,035.20 9,699.20

Caplin Point Laboratories Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,126.80 2,167.20 2,459.60 2,453.90 2,618.50

Competitive Comparison of Caplin Point Laboratories's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Caplin Point Laboratories's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's Gross Profit distribution charts can be found below:

* The bar in red indicates where Caplin Point Laboratories's Gross Profit falls into.



Caplin Point Laboratories Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Caplin Point Laboratories's Gross Profit for the fiscal year that ended in Mar. 2024 is calculated as

Gross Profit (A: Mar. 2024 )=Revenue - Cost of Goods Sold
=16941 - 7241.8
=9,699

Caplin Point Laboratories's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=4532.2 - 1913.7
=2,619

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹9,699 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Caplin Point Laboratories's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=2,619 / 4532.2
=57.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Caplin Point Laboratories  (BOM:524742) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Caplin Point Laboratories had a gross margin of 57.78% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Caplin Point Laboratories Gross Profit Related Terms

Thank you for viewing the detailed overview of Caplin Point Laboratories's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Caplin Point Laboratories (BOM:524742) Business Description

Traded in Other Exchanges
Address
Ashvich Tower, Developed Plots Industrial Estate, No. 3, 3rd Floor, Perungudi, Chennai, TN, IND, 600 096
Caplin Point Laboratories Ltd is the India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, liquid orals, dry powder, soft gels, penems injections, suppositories. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops. The business of the company is organized into the following product segments, Antibiotics, Nsaids, Ophthalmics, Pain Management, and Antiulcers. Its products have a presence in the Latin American and African markets.

Caplin Point Laboratories (BOM:524742) Headlines

No Headlines